ClinicalTrials.gg
CompletedNCT00675948Updated May 3, 2023Results posted

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

A Phase 3 interventional study of Sativex and GW-2000-02 in Pain and Cancer, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.

Enrollment
16th of 17
43 · median 246
Started
2002
with 5 others
Phase 3
15 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
14 of 17
Jazz Pharmaceuticals

Among the 17 studies testing nabiximols in Pain, this one is the 16th largest by enrollment, is one of 6 that started in 2002, is one of 15 in phase 3, and was the 3rd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →

About nabiximols

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing nabiximols in Pain as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® and GW-2000-02.

Read the detailed description

Subjects who have previously participated in GWCA0101, a two week (two days baseline and two weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex® (containing delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) and GW-2000-02 (containing THC alone) in subjects with cancer-related pain are screened, and if eligible begin dosing with open-label Sativex®. They are allowed to self-titrate their study medication to symptom resolution or maximum tolerated/allowable dose of 130 mg THC and 120 mg CBD and have the opportunity to request a change from Sativex® to GW-2000-02 if they or the investigator consider their response less than optimal. Subjects are reviewed for tolerability and evidence of clinical benefit at 7-10 days after Visit 1 and then every four weeks. Continuation within the study is conditional on satisfactory reports of tolerability, efficacy and dosing regime.

03

Conditions studied

  • Pain
  • Cancer

Keywords

  • Palliative Care
  • Pain
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and eligible to continue into the extension study from GWCA0101.
  • Complied adequately with the study requirements, as detailed in GWCA0101.
  • In the investigator's opinion able to undertake and comply with all of the study requirements (it is understood that progress of the disease may accelerate and affect this ability).
  • Willing and able to read, consider and understand the subject information and consent form and to give written in compliance with the Declaration of Helsinki1.
  • Willing to allow their own general practitioner, and consultant if appropriate, to be informed of study participation.
  • Willing for their name to be notified to the Home Office for participation in the trial.

Exclusion criteria

Exclusion Criteria:

  • Have not participated in GWCA0101.
  • Have not complied adequately with the study requirements, as detailed in GWCA0101.
  • Experienced an unacceptable adverse event, whilst participating in GWCA0101.
  • Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
  • History of any type of schizophrenia, any other psychotic illness, a serious personality disorder, or other significant psychiatric illness other than depression associated with their chronic pain and/or in response to the underlying condition.
  • Currently taking levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
  • Has a serious cardiovascular disorder, including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
  • Has significant renal or hepatic impairment, which in the opinion of the investigator, are unsuitable for treatment with Medicinal Product.
  • History of epilepsy.
  • Female subjects of child bearing potential and male subjects whose partner is of child bearing potential, unless willing to ensure that they or their partner use effective during the study and for three months thereafter.
  • If female, are pregnant or lactating, or are planning pregnancy during the course of the study and for three months thereafter.
  • Have oral cavity cancers or whose previous treatments had included radiotherapy to the floor of the mouth.
  • In the opinion of the investigator, are unsuitable to participate in the study for any other reason, not mentioned in the inclusion and exclusion criteria.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Sativex

    Active treatment

    Drug: Sativex

  • Experimental
    GW-2000-02

    Active treatment

    Drug: GW-2000-02

Interventions

  • Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.

    Also known as: GW-1000-02

  • DrugGW-2000-02

    Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.

06

What researchers measure

Primary outcomes

  1. The Incidence of Adverse Events as a Measure of Subject Safety

    The number of subjects who experienced an adverse event in this study is presented.

    Time frame: 0 - 657 days

Secondary outcomes

  1. Change From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment

    The Brief Pain Inventory (Short Form) is a 14-item questionnaire that asks subjects to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items (range 0-10). The minimum value is zero and maximum is 10. A negative value indicates an improvement in score from baseline. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of the mean Brief Pain Inventory (Short Form) score was only carried out when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.

    Time frame: 0 - 657 days

  2. Change From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment

    The EORTC Quality of Life-C30 Health Status visual analogue scale was a self-reported score where subjects rated their health state from: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score from baseline indicates an improvement in condition. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of mean EORTC Quality of Life-C30 Health Status scores was only produced when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.

    Time frame: 0 - 657 days

07

Results

Posted Sep 13, 2012

Participant flow

The first subject was recruited on the 30th April 2002

Participant flow — Overall Study
MilestoneSativexTHC Alone
Started394
Completed01
Not completed393
Withdrew: Adverse event231
Withdrew: Lack of efficacy30
Withdrew: Withdrawal by subject70
Withdrew: Lost to follow-up20
Withdrew: Protocol violation10
Withdrew: Pain under control10
Withdrew: Sponsor decision01
Withdrew: Patient died10
Withdrew: Patient unable to comply with diaries10
Withdrew: Patient feels unable to take medication01

Outcome measures

PrimaryThe Incidence of Adverse Events as a Measure of Subject Safety

The number of subjects who experienced an adverse event in this study is presented.

Time frame:
0 - 657 days
Reported as:
Number · participants
The Incidence of Adverse Events as a Measure of Subject Safety
participantsSativexTHC Alone
The Incidence of Adverse Events as a Measure of Subject Safety374
SecondaryChange From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment

The Brief Pain Inventory (Short Form) is a 14-item questionnaire that asks subjects to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items (range 0-10). The minimum value is zero and maximum is 10. A negative value indicates an improvement in score from baseline. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of the mean Brief Pain Inventory (Short Form) score was only carried out when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.

Time frame:
0 - 657 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment
units on a scaleSativexTHC Alone
Change From Baseline in the Mean Brief Pain Inventory (Short Form) - Pain Severity Score at the End of Treatment-0.53 ± 1.28—
SecondaryChange From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment

The EORTC Quality of Life-C30 Health Status visual analogue scale was a self-reported score where subjects rated their health state from: 0 = worst health state imaginable to 100 = best health state imaginable. An increase in score from baseline indicates an improvement in condition. The end of treatment was classed as study completion or withdrawal, if this occurred sooner. Calculation of mean EORTC Quality of Life-C30 Health Status scores was only produced when data was available for 10 or more subjects at the relevant study visits. As such, no mean scores were calculated for subjects taking THC alone.

Time frame:
0 - 657 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment
units on a scaleSativexTHC Alone
Change From Baseline in the Mean EORTC Quality of Life-C30 Questionnaire - Global Health Status Score at the End of Treatment-2.0 ± 28.34—

Adverse events

Collected over All adverse events (AEs) occurring from the time of consent to post study follow up (2 - 521 days) were collected. All deaths and serious adverse events (SAEs) occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sativex—20/39 (51.3%)37/39 (94.9%)
THC Alone—1/4 (25%)4/4 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventSativexTHC Alone
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/391/4
HaematemesisGastrointestinal disorders2/390/4
ConfusionPsychiatric disorders2/390/4
Anaemia NOS aggravatedBlood and lymphatic system disorders1/390/4
Atrial fibrillationCardiac disorders1/390/4
Diarrhoea NOSGastrointestinal disorders1/390/4
Intestinal obstruction NOSGastrointestinal disorders1/390/4
NauseaGastrointestinal disorders1/390/4
Vomiting NOSGastrointestinal disorders1/390/4
General physical health deteriorationGeneral disorders1/390/4
Most frequent other events
Showing 10 of 50
Most frequent other events
EventSativexTHC Alone
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/391/4
NauseaGastrointestinal disorders10/390/4
VomitingGastrointestinal disorders10/391/4
DizzinessNervous system disorders8/391/4
HeadacheNervous system disorders2/391/4
Memory impairmentNervous system disorders0/391/4
ConfusionPsychiatric disorders7/391/4
ArthralgiaMusculoskeletal and connective tissue disorders0/391/4
CholelithiasisHepatobiliary disorders0/391/4
CellulitisInfections and infestations0/391/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SativexTHC AloneTotal
<=18 years000
Between 18 and 65 years29433
>=65 years10010
Age, Continuous
Age, Continuous(years)SativexTHC AloneTotal
Mean57.5 ± 13.558.6 ± 6.2857.6 ± 12.94
Sex: Female, Male
Sex: Female, Male(Participants)SativexTHC AloneTotal
Female16319
Male23124
Region of Enrollment
Region of Enrollment(participants)SativexTHC AloneTotal
United Kingdom31334
Belgium819
08

Study locations

1 site
  • Shropshire and Mid-Wales Hospice
    Shrewsbury, SY3 8HS, United Kingdom
09

References and documents

Publications

  • Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013 Aug;46(2):207-18. doi: 10.1016/j.jpainsymman.2012.07.014. Epub 2012 Nov 8. PubMed 23141881 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2008
First posted
May 12, 2008
Start
Apr 2002
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Results first posted
Sep 13, 2012
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00675948
Responsible party
Sponsor
First posted
May 12, 2008
Start date
Apr 2002
Primary completion
Sep 2006
Completion
Sep 2006
Results posted
Sep 13, 2012
Last update
May 3, 2023

Study contacts

Jeremy R Johnson, MB ChB
principal investigator · Shropshire and Mid-Wales Hospice

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nabiximols

Start the discussion